Metabolic reprogramming by adenosine antagonism and implications in non-small cell lung cancer therapy.

Authors:
Guan S; Suman S; Amann JM; Wu R; Carbone DP and 2 more

Journal:
Neoplasia

Publication Year: 2022

DOI:
10.1016/j.neo.2022.100824

PMCID:
PMC9344351

PMID:
35914370

Journal Information

Full Title: Neoplasia

Abbreviation: Neoplasia

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Authors declare no conflict of interest."

Evidence found in paper:

"The work was supported by National Institutes of Health Grants R01 CA248741 and R01 CA175370 (MMD and DPC), Dallapezze Fund (DPC and MMD), OSU Pelotonia Awards (MMD), National key research and development project (2019YFC1315700), National Natural Sciences Foundation Key Program (81630071), National Natural Science Foundation General Program (81871889, 81972905), Aiyou Foundation (KY201701) DPC, MMD, JW, SG - Conceptualization; DPC, MMD, JW - Funding acquisition; DPC, MMD, JW, JMA - Supervision; SG, SS - Data collection; SG - Writing original draft; SG, JW, DPC, MMD, JMA, RW - Writing - review & editing."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025